(IN BRIEF) Alexion, AstraZeneca Rare Disease, has secured FDA acceptance and Priority Review for its supplemental Biologics License Application for Ultomiris as a potential treatment for adults with immunoglobulin A nephropathy, a rare inflammatory kidney disease that can progress to … Read the full press release →
Posted in European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Alexion, Alexion’s Ultomiris Receives Priority Review in the US for Adults Living with Immunoglobulin A Nephropathy, ALXN1210-IgAN-320, AstraZeneca, AstraZeneca Rare Disease, AstraZeneca Rare Disease Advances Ultomiris Regulatory Review in the US for Rare Kidney Disease IgAN, atypical haemolytic uraemic syndrome, C5 complement inhibitor, Chronic kidney disease, complement science, EGFR, end-stage kidney disease, estimated glomerular filtration rate, European Renal Association Congress, FDA priority review, generalised myasthenia gravis, glomeruli, I CAN Phase III trial, IgAN, immunoglobulin A nephropathy, inflammation, Marc Dunoyer, nephrology, neuromyelitis optica spectrum disorder, paroxysmal nocturnal haemoglobinuria, PDUFA, proteinuria, rare disease medicine, rare kidney disease, ravulizumab, sBLA, supplemental Biologics License Application, terminal complement pathway, Ultomiris, Ultomiris Moves Toward Potential US Approval in IgAN After Interim Phase III Data Show Significant Proteinuria Reduction, UPCR, urine protein creatinine ratio, US Food and Drug Administration
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
